Valuation: DMS

Market Cap 27.99M 32.34M 26.06M 23.95M 45.3M 3.08B 45.89M 307M 121M 1.54B 121M 119M 5.08B P/E 2026 *
36x
P/E 2027 * 10.8x
Enterprise Value 43.39M 50.14M 40.41M 37.13M 70.23M 4.77B 71.13M 476M 187M 2.38B 188M 184M 7.87B EV / Sales 2026 *
0.76x
EV / Sales 2027 * 0.55x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 32.2M
-0.84%+5.24%-13.34%-16.71% 14.02B
+4.81%-6.82%+38.55%-12.19% 3.9B
+1.81%+11.70%-36.35%-55.26% 1.27B
+1.98%+9.99%-35.86%-43.67% 1.18B
-4.57%-3.84%+37.31%+102.09% 1.16B
+1.35%+5.63%-45.42% - 952M
+17.03%+10.93%+29.15%+99.38% 500M
-1.79%+1.39%+68.29% - 329M
+0.36%+2.02%-59.27%+221.90% 265M
Average +2.01%+1.42%-1.88%+42.22% 2.62B
Weighted average by Cap. +0.66%+2.16%-4.41%-7.92%

Financials

2026 *2027 *
Net sales 56.8M 65.64M 52.9M 48.61M 91.94M 6.24B 93.12M 624M 245M 3.12B 246M 241M 10.31B 65.9M 76.16M 61.37M 56.39M 107M 7.24B 108M 724M 284M 3.62B 285M 279M 11.96B
Net income 800K 924K 745K 685K 1.29M 87.93M 1.31M 8.78M 3.45M 43.93M 3.46M 3.39M 145M 2.6M 3M 2.42M 2.22M 4.21M 286M 4.26M 28.55M 11.2M 143M 11.25M 11.03M 472M
Net Debt 15.4M 17.8M 14.34M 13.18M 24.93M 1.69B 25.25M 169M 66.33M 846M 66.66M 65.31M 2.79B 8M 9.24M 7.45M 6.85M 12.95M 879M 13.12M 87.83M 34.46M 439M 34.63M 33.93M 1.45B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-